A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2014-02-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-014-1524-0PMID 24514956PMCID PMC6314199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  2013cited by this paper
• Up‐regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration‐resistant prostate cancer

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

  2012cited by this paper
• Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• Tim-3-Expressing CD4+ and CD8+ T Cells in Human Tuberculosis (TB) Exhibit Polarized Effector Memory Phenotypes and Stronger Anti-TB Effector Functions

  2012cited by this paper
• Myeloid derived suppressor cells in human diseases.

  2011cited by this paper
• Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

  2011cited by this paper
• The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.

  2011cited by this paper
• CD56brightCD16+ NK Cells: A Functional Intermediate Stage of NK Cell Differentiation

  2011cited by this paper
• Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

  2011cited by this paper
• Protective Effector Memory CD4 T Cells Depend on ICOS for Survival

  2011cited by this paper
• Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group.

  2011cited by this paper
• Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

  2010cited by this paper
• Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer

  2010cited by this paper
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

  2010cited by this paper
• Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

  2009cited by this paper
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cited by this paper
• Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment

  2009cited by this paper
• Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.

  2009cited by this paper
• Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses

  2007cited by this paper
• The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells

  2007cited by this paper
• Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Multiple Costimulatory Modalities Enhance CTL Avidity

  2005cited by this paper
• Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL1

  2005cited by this paper
• The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors

  2005cited by this paper
• Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy.

  2005cited by this paper
• Primary antitumor immune response mediated by CD4+ T cells.

  2005cited by this paper
• Central memory and effector memory T cell subsets: function, generation, and maintenance.

  2004cited by this paper
• Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

  2003cited by this paper
• T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

  2001cited by this paper
• A triad of costimulatory molecules synergize to amplify T-cell activation.

  1999cited by this paper
• Activation-induced expression of human programmed death-1 gene in T-lymphocytes.

  1997cited by this paper
• Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma.

  1994cited by this paper

• The efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A meta-analysis and reconstructed individual patient data analysis.

  2026cites this paper
• NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management

  2025cites this paper
• The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise

  2025cites this paper
• The role of immunotherapy in urological cancers.

  2024cites this paper
• Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations

  2024cites this paper
• Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives

  2023cites this paper
• Emerging Biomarker-Guided Therapies in Prostate Cancer

  2022cites this paper
• Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma

  2022cites this paper
• A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice

  2022cites this paper
• Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer

  2022cites this paper
• Immune mechanisms behind prostate cancer in men of African ancestry: A review

  2022cites this paper
• The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention

  2022cites this paper
• The emerging field of oncolytic virus-based cancer immunotherapy.

  2022cites this paper
• Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.

  2022cites this paper
• The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma

  2022cites this paper
• Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

  2021cites this paper
• Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade

  2021cites this paper
• Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

  2021cites this paper
• Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

  2021cites this paper
• FLOW CYTOMETRIC EVALUATION OF PERIPHERAL BLOOD BIOMARKERS FOR SOLID TUMOURS IMMUNOTHERAPY GUIDING: A REVIEW

  2021cites this paper
• Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

  2021cites this paper
• Cholesterol metabolism in prostate cancer

  2021cites this paper
• Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer

  2020cites this paper
• Immunotherapy, Inflammation and Colorectal Cancer

  2020cites this paper
• Nanomedicine for the Treatment of Advanced Prostate Cancer

  2020cites this paper
• Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised

  2020cites this paper
• Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment

  2019cites this paper
• Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

  2019cites this paper
• Drug-Induced Injury, Polyps, Congenital, and Miscellaneous Disorders

  2019cites this paper
• The evolving landscape of immunotherapy in advanced prostate cancer.

  2019cites this paper
• A Review on Anticancer Peptide‐Based Vaccines: Advantages, Limitations and Current Challenges

  2019cites this paper
• Urologic Malignancies

  2019cites this paper
• Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?

  2019cites this paper
• A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

  2019cites this paper
• Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

  2018cites this paper
• An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression

  2018cites this paper
• Correlates of immune and clinical activity of novel cancer vaccines.

  2018cites this paper
• Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.

  2018cites this paper
• Current Role of Checkpoint Inhibitors in Urologic Cancers.

  2018cites this paper
• Genetics and biology of prostate cancer

  2018cites this paper
• Design and delivery strategies of alphavirus replicon-based cervical cancer vaccines

  2018cites this paper
• 13 – Cancer Vaccines

  2018cites this paper
• Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations

  2017cites this paper
• Pneumotoxicity associated with immune checkpoint inhibitor therapies

  2017cites this paper
• PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.

  2017cites this paper
• Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

  2017cites this paper
• T-cell immunoglobulin and mucin-domain containing-3 in malignant cancers

  2017cites this paper
• Radiotherapy and immunotherapy: a beneficial liaison?

  2017cites this paper
• Cancer Vaccines: A Brief Overview.

  2016cites this paper
• Rekindling cancer vaccines

  2016cites this paper
• Regulation of prostate cancer progression by the tumor microenvironment.

  2016cites this paper
• Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells

  2016cites this paper
• Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

  2016cites this paper
• Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors

  2016cites this paper
• The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements

  2016cites this paper
• Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

  2016cites this paper
• Cancer immunotherapy: new applications in urologic oncology

  2016cites this paper
• A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy

  2016cites this paper
• A New Era of Immunotherapy in Prostate Cancer.

  2016cites this paper
• Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

  2016cites this paper
• Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm

  2016cites this paper
• Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

  2016influential citation
• Tn-MUC 1 DC Vaccination of Rhesus Macaques and a Phase I / II Trial in Patients with Non-Metastatic Castrate Resistant Prostate Cancer

  2016cites this paper
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

  2016cites this paper
• esigning a broad-spectrum integrative approach for cancer revention and treatment

  2016cites this paper
• Cancer vaccines: limited success but the research should remain viable

  2016cites this paper
• Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

  2016cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• Immune Therapy for Prostate Cancer

  2016influential citation
• Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

  2015cites this paper
• Systematic review: colitis associated with anti‐CTLA‐4 therapy

  2015cites this paper
• Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

  2015cites this paper
• Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State

  2015cites this paper
• Eradication of established murine mesothelioma tumours by combined immunotherapy

  2015cites this paper
• Application of biomarkers in oncology clinical trials

  2015cites this paper
• Development of therapeutic vaccine strategies and pre-clinical animal tumor models for head and neck cancers

  2015cites this paper
• Designing a broad-spectrum integrative approach for cancer prevention and treatment

  2015cites this paper
• Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer

  2015cites this paper
• A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

  2015cites this paper
• Immunotherapy in Urologic Cancer : Evolving Roles for Targeting of CTLA-4 , PD-1 / PD-L 1 , and HLA-G

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer

  2015cites this paper
• B7-H1/PD-1 Blockade Therapy in Urological Malignancies: Current Status and Future Prospects

  2015cites this paper
• Emerging agents for the therapy of advanced prostate cancer.

  2015cites this paper
• Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab

  2015cites this paper
• Targeting the adaptive molecular landscape of castration-resistant prostate cancer

  2015cites this paper
• Immune Infiltration and Prostate Cancer

  2015cites this paper
• Designing a broad-spectrum integrative approach for cancer prevention and treatment.

  2015cites this paper
• Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

  2015cites this paper
• Critical issues in cancer vaccine trial design.

  2015cites this paper
• Checkpoint blockade in combination with cancer vaccines.

  2015cites this paper
• Prostate cancer vaccines: the long road to clinical application

  2015influential citation
• Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances

  2014cites this paper
• Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies

  2014cites this paper
• Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

  2014cites this paper
• PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

  2014cites this paper
• Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer

  2014cites this paper
• Adding fuel to the fire: Immunogenic intensification

  2014cites this paper